Pharmacokinetic Correlation of Structurally Modified Chalcone Derivatives As Promising Leads to Treat Tuberculosis

References

• Miggiano R , RizziM , FerrarisDM. Mycobacterium tuberculosis pathogenesis, infection prevention and treatment. Pathogens9(5), 1–82020).
   Web of Science ®Google Scholar
• Keshavjee S , FarmerPE. Tuberculosis, drug resistance, and the history of modern medicine. N. Engl. J. Med.367(10), 931–936 (2012).
   PubMed Web of Science ®Google Scholar
• Kaufmann SHE . Vaccine development against tuberculosis over the last 140 years: failure as part of success. Front. Microbiol.12, 1–12 (2021).
   Web of Science ®Google Scholar
• Calmette A . Preventive vaccination against tuberculosis with BCG. Proc. R. Soc. Med.24(11), 1481–1490 (1931).
   PubMedGoogle Scholar
• Verma AK , KalraOP. Discovery of new drugs against tuberculosis: history guides. Arch. Clin. Infect. Dis.7(4), 109–112 (2012).
   Google Scholar
• Davies PDO . The role of DOTS in tuberculosis treatment and control. Am. J. Respir. Med.2(3), 203–209 (2003).
   PubMedGoogle Scholar
• Magis-Escurra C , vanden Boogaard J , IjdemaD , BoereeM , AarnoutseR. Therapeutic drug monitoring in the treatment of tuberculosis patients. Pulm. Pharmacol. Ther.25(1), 83–86 (2012).
   PubMed Web of Science ®Google Scholar
• Burman W , BenatorD , VernonAet al. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am. J. Respir. Crit. Care Med.173(3), 350–356 (2006).
   PubMed Web of Science ®Google Scholar
• Nijland HM , RuslamiR , StalenhoefJEet al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin. Infect. Dis.43(7), 848–854 (2006).
   PubMed Web of Science ®Google Scholar
• Boulanger C , HollenderE , FarrellKet al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir–ritonavir in patients with HIV infection and active tuberculosis. Clin. Infect. Dis.49(9), 1305–1311 (2009).
   PubMed Web of Science ®Google Scholar
• Ruslami R , NijlandHM , AdhiartaIGet al. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob. Agents Chemother.54(3), 1068–1074 (2010).
   PubMed Web of Science ®Google Scholar
• Xu Y , WuJ , LiaoS , SunZ. Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes. Ann. Clin. Microbiol. Antimicrob.16(1), 67 (2017).
   PubMedGoogle Scholar
• Widyarti S , KamaruddinM , AristyaniSet al. Bioinorganic chemistry and computational study of herbal medicine to treatment of tuberculosis. In: Medicinal Plants.HassanBAR ( Ed.). IntechOpen, Rijeka, Croatia (2019).
   Google Scholar
• Salehi B , QuispeC , ChamkhiIet al. Pharmacological properties of chalcones: a review of preclinical including molecular mechanisms and clinical evidence. Front. Pharmacol.11, (2021).
   Web of Science ®Google Scholar
• Zhuang C , ZhangW , ShengC , ZhangW , XingC , MiaoZ. Chalcone: a privileged structure in medicinal chemistry. Chem. Rev.117(12), 7762–7810 (2017).
   PubMed Web of Science ®Google Scholar
• Daina A , MichielinO , ZoeteV. iLOGP: a simple, robust, and efficient description of n-octanol/water partition coefficient for drug design using the GB/SA approach. J. Chem. Inf. Model.54(12), 3284–3301 (2014).
   PubMed Web of Science ®Google Scholar
• Benet LZ , HoseyCM , UrsuO , OpreaTI. BDDCS, the rule of 5 and drugability. Adv. Drug Deliv. Rev.101, 89–98 (2016).
   PubMed Web of Science ®Google Scholar
• Pollastri MP . Overview on the rule of five. Curr. Protoc. Pharmacol.Chapter 9, Unit 9.12 (2010).
   PubMedGoogle Scholar
• Lipinski CA , LombardoF , DominyBW , FeeneyPJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev.23(1), 3–25 (1997).
   Web of Science ®Google Scholar
• Fullam E , YoungRJ. Physicochemical properties and Mycobacterium tuberculosis transporters: keys to efficacious antitubercular drugs?RSC Med. Chem.12(1), 43–56 (2021).
   Google Scholar
• van Staden D , HaynesRK , ViljoenJM. Adapting clofazimine for treatment of cutaneous tuberculosis by using self-double-emulsifying drug delivery systems. Antibiotics (Basel)11(6), 806 (2022).
   PubMed Web of Science ®Google Scholar
• Stanley RE , BlahaG , GrodzickiRL , StricklerMD , SteitzTA. The structures of the anti-tuberculosis antibiotics viomycin and capreomycin bound to the 70S ribosome. Nat. Struct. Mol. Biol.17(3), 289–293 (2010).
   PubMed Web of Science ®Google Scholar
• Fernandes GFS , ThompsonAM , CastagnoloD , DennyWA , DosSantos JL. Tuberculosis drug discovery: challenges and new horizons. J. Med. Chem.65(11), 7489–7531 (2022).
   PubMed Web of Science ®Google Scholar
• Elkanzi NAA , HrichiH , AlolayanRA , DerafaW , ZahouFM , BakrRB. Synthesis of chalcones derivatives and their biological activities: a review. ACS Omega7(32), 27769–27786 (2022).
   PubMed Web of Science ®Google Scholar
• Pires DEV , BlundellTL , AscherDB. pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J. Med. Chem.58(9), 4066–4072 (2015).
   PubMed Web of Science ®Google Scholar
• Alzahabi KH , UsmaniO , GeorgiouTKet al. Approaches to treating tuberculosis by encapsulating metal ions and anti-mycobacterial drugs utilizing nano- and microparticle technologies. Emerg. Top. Life Sci.4(6), 581–600 (2020).
   PubMedGoogle Scholar
• Sorkun MC , KhetanA , ErS. AqSolDB, a curated reference set of aqueous solubility and 2D descriptors for a diverse set of compounds. Sci. Data6(1), 143 (2019).
   PubMedGoogle Scholar
• Ahmed I , LeachDN , WohlmuthH , DeVoss JJ , BlanchfieldJT. Caco-2 cell permeability of flavonoids and saponins from Gynostemma pentaphyllum: the immortal herb. ACS Omega5(34), 21561–21569 (2020).
   PubMed Web of Science ®Google Scholar
• Yan A , WangZ , CaiZ. Prediction of human intestinal absorption by GA feature selection and support vector machine regression. Int. J. Mol. Sci.9(10), 1961–1976 (2008).
   PubMed Web of Science ®Google Scholar
• Sharom FJ . The P-glycoprotein multidrug transporter. Essays Biochem.50(1), 161–178 (2011).
   PubMed Web of Science ®Google Scholar
• Dewanjee S , DuaTK , BhattacharjeeNet al. Natural products as alternative choices for P-glycoprotein (P-gp) inhibition. Molecules22(6), 871 (2017).
   PubMed Web of Science ®Google Scholar
• Amin ML . P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights7, 27–34 (2013).
   PubMedGoogle Scholar
• Øie S . Drug distribution and binding. J. Clin. Pharmacol.26(8), 583–586 (1986).
   PubMed Web of Science ®Google Scholar
• Krauß J , BracherF. Pharmacokinetic enhancers (boosters) – escort for drugs against degrading enzymes and beyond. Sci. Pharm.86(4), 43 (2018).
   Google Scholar
• Gatwiri W , KagiaR. Identification of potential compounds for the management of multidrug-resistant tuberculosis using computational methods [version 1; peer review: awaiting peer review]. F1000Res.12, 298 (2023).
   Google Scholar
• Vijay U , GuptaS , MathurP , SuravajhalaP , BhatnagarP. Microbial mutagenicity assay: Ames test. Bio Protoc.8(6), e2763 (2018).
   PubMedGoogle Scholar
• He S , YeT , WangRet al. An in silico model for predicting drug-induced hepatotoxicity. Int. J. Mol. Sci.20(8), 1–12 (2019).
   Web of Science ®Google Scholar
• Gadaleta D , VukovićK , TomaCet al. SAR and QSAR modeling of a large collection of LD50 rat acute oral toxicity data. J. Cheminform.11(1), 58 (2019).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Silva NC , ProkopczykMI , DosSantos JL. The medicinal chemistry of chalcones as anti-Mycobacterium tuberculosis agents. Mini Rev. Med. Chem.22(16), 2068–2080 (2022).
   PubMed Web of Science ®Google Scholar
• Tekale S , MasheleS , PooeO , ThoreS , KendrekarP , PawarR. Biological role of chalcones in medicinal chemistry. In: Vector-Borne Diseases.ClabornD, BhattacharyaS, RoyS ( Eds). IntechOpen, Rijeka, Croatia (2020).
   Google Scholar
• Leite FF , de SousaNF , de OliveiraBHet al. Anticancer activity of chalcones and its derivatives: review and in silico studies. Molecules28(10), (2023).
   Web of Science ®Google Scholar
• Shalaby MA , RizkSA , FahimAM. Synthesis, reactions and application of chalcones: a systematic review. Org. Biomol. Chem.21(26), 5317–5346 (2023).
   PubMed Web of Science ®Google Scholar
• Dartois VA , RubinEJ. Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nat. Rev. Microbiol.20(11), 685–701 (2022).
   PubMed Web of Science ®Google Scholar
• Lienhardt C , RaviglioneM , SpigelmanMet al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J. Infect. Dis.205(Suppl. 2), S241–S249 (2012).
   PubMedGoogle Scholar
• Akhtar MS , RehmanAU , ArshadHet al. In vitro antioxidant activities and the therapeutic potential of some newly synthesized chalcones against 4-acetaminophenol induced hepatotoxicity in rats. Dose Response19(1), 1559325821996955 (2021).
   Web of Science ®Google Scholar
• Yang Y , ZhuZ , Adu-FrimpongMet al. Micelles of licorice chalcone A for oral administration: preparation, in vitro, in vivo, and hepatoprotective activity evaluation. J. Nanopart. Res.24(6), 110 (2022).
   Web of Science ®Google Scholar
• Singh H , SidhuS , ChopraK , KhanMU. Hepatoprotective effect of trans-chalcone on experimentally induced hepatic injury in rats: inhibition of hepatic inflammation and fibrosis. Can. J. Physiol. Pharmacol.94(8), 879–887 (2016).
   PubMed Web of Science ®Google Scholar
• Karimi-Sales E , MohaddesG , AlipourMR. Chalcones as putative hepatoprotective agents: preclinical evidence and molecular mechanisms. Pharmacol. Res.129, 177–187 (2018).
   PubMed Web of Science ®Google Scholar
• Islam S , SalekeenR , AshrafA. Computational screening of natural MtbDXR inhibitors for novel anti-tuberculosis compound discovery. J. Biomol. Struct. Dyn.42(06), 1–11 (2023).
   PubMedGoogle Scholar
• Chiaradia LD , MartinsPGA , CordeiroMNSet al. Synthesis, biological evaluation, and molecular modeling of chalcone derivatives as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatases (PtpA and PtpB). J. Med. Chem.55(1), 390–402 (2012).
   PubMed Web of Science ®Google Scholar
• Sabarathinam S , GanamuraliN. Chalcones reloaded: an integration of network pharmacology and molecular docking for type 2 diabetes therapy. J. Biomol. Struct. Dyn.43(7), 1–13 (2023).
   Google Scholar